Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | METAP1 | P53582 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | F12 | P00748 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2385078 | 0.87 | HRH4 (0.51) | HRH4HIF1AALDH1A1SMN1; SMN2METAP1 | |
| SCHEMBL2382683 | 0.80 | HRH4 (0.76) | HRH4HIF1AALDH1A1SMN1; SMN2HTR3A | |
| SCHEMBL2387088 | 0.79 | HRH4 (0.61) | HRH4ALDH1A1HTR3AKDM4ETDP1 | |
| SCHEMBL2381880 | 0.78 | HRH4 (0.72) | HRH4ALDH1A1HTR3AKDM4E | |
| SCHEMBL2384690 | 0.78 | HRH4 (0.76) | HRH4HIF1AALDH1A1SMN1; SMN2HTR3A | |
| SCHEMBL2385670 | 0.76 | CYP1A2 (0.66) | HRH4HIF1AALDH1A1HTR3AKDM4E | |
| SCHEMBL26675182 | 0.76 | SMN1; SMN2 (0.53) | HRH4HIF1AALDH1A1SMN1; SMN2METAP1 | |
| SCHEMBL2386809 | 0.75 | HRH4 (0.57) | HRH4HIF1AALDH1A1HTR3AKDM4E | |
| SCHEMBL3616834 | 0.75 | KDM4E (0.77) | HIF1AALDH1A1SMN1; SMN2METAP1KDM4E | |
| SCHEMBL2384326 | 0.75 | HRH4 (0.76) | HRH4ALDH1A1HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009035671-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | claimed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | claimed |
| US-8022209-B2 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-20 | — | — | US | disclosed |
| US-8022209-B2 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-20 | — | — | US | disclosed |
| US-8022209-B2 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-20 | — | — | US | disclosed |
| WO-2009035671-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009035671-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | disclosed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | HRH4 1/4885HIF1A 1874/4885ALDH1A1 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.